Your browser is no longer supported. Please, upgrade your browser.
Theravance Biopharma, Inc.
Index- P/E- EPS (ttm)-4.73 Insider Own6.40% Shs Outstand63.30M Perf Week-7.93%
Market Cap1.11B Forward P/E- EPS next Y-2.85 Insider Trans-0.29% Shs Float51.21M Perf Month-6.53%
Income-285.20M PEG- EPS next Q-1.02 Inst Own87.10% Short Float6.59% Perf Quarter6.65%
Sales82.60M P/S13.41 EPS this Y-6.50% Inst Trans2.87% Short Ratio10.08 Perf Half Y-3.51%
Book/sh-4.13 P/B- EPS next Y36.80% ROA-54.60% Target Price31.22 Perf Year-27.18%
Cash/sh5.60 P/C3.09 EPS next 5Y6.70% ROE134.90% 52W Range14.48 - 31.35 Perf YTD-2.59%
Dividend- P/FCF- EPS past 5Y10.60% ROI-106.70% 52W High-44.78% Beta0.93
Dividend %- Quick Ratio4.30 Sales past 5Y44.40% Gross Margin- 52W Low19.54% ATR1.03
Employees316 Current Ratio4.30 Sales Q/Q47.60% Oper. Margin- RSI (14)34.01 Volatility6.41% 5.57%
OptionableYes Debt/Eq- EPS Q/Q-11.20% Profit Margin- Rel Volume1.15 Prev Close17.49
ShortableYes LT Debt/Eq- EarningsFeb 23 AMC Payout- Avg Volume334.87K Price17.31
Recom2.20 SMA20-9.60% SMA50-6.70% SMA200-11.54% Volume385,245 Change-1.03%
Oct-14-20Upgrade Morgan Stanley Equal-Weight → Overweight $32
Jul-07-20Initiated JP Morgan Overweight $29
Jun-15-20Initiated Morgan Stanley Equal-Weight $30
May-13-20Initiated Cowen Outperform $42
Jan-08-20Reiterated H.C. Wainwright Buy $25 → $30
Nov-06-19Upgrade Robert W. Baird Underperform → Neutral $22 → $18
Oct-29-19Initiated H.C. Wainwright Buy $25
Mar-29-18Resumed Piper Jaffray Overweight $45
Aug-17-17Initiated Evercore ISI Outperform $45
Jun-16-17Initiated Cantor Fitzgerald Overweight $55
May-11-17Reiterated Needham Buy $40 → $45
Dec-21-16Initiated Needham Buy $40
Nov-03-16Initiated Piper Jaffray Overweight
Oct-12-16Downgrade Robert W. Baird Neutral → Underperform $19 → $24
Aug-03-16Downgrade BofA/Merrill Neutral → Underperform
Jun-20-16Reiterated Leerink Partners Outperform $26 → $29
Jun-20-16Initiated Guggenheim Buy $30
May-12-16Initiated Leerink Partners Outperform $26
May-05-16Downgrade BofA/Merrill Buy → Neutral
Feb-03-15Upgrade Robert W. Baird Underperform → Neutral $13 → $17
Feb-24-21 06:32AM  
Feb-23-21 04:45PM  
Feb-22-21 10:16AM  
Feb-10-21 06:00AM  
Feb-09-21 06:00AM  
Jan-14-21 12:00PM  
Jan-05-21 06:00AM  
Dec-19-20 01:06PM  
Dec-05-20 11:32AM  
Nov-17-20 06:00AM  
Nov-09-20 12:17PM  
Nov-07-20 01:31AM  
Nov-05-20 07:05PM  
Oct-29-20 12:34PM  
Oct-27-20 01:19PM  
Oct-22-20 06:00AM  
Oct-19-20 10:39AM  
Sep-05-20 11:31AM  
Sep-01-20 06:00AM  
Aug-07-20 01:27PM  
Aug-06-20 06:35PM  
Jul-30-20 12:34PM  
Jul-27-20 06:00AM  
Jul-22-20 12:32PM  
Jul-02-20 06:00AM  
Jun-29-20 03:50PM  
Jun-26-20 12:04PM  
Jun-25-20 08:26AM  
Jun-17-20 09:38PM  
Jun-15-20 09:57AM  
Jun-05-20 11:31AM  
Jun-02-20 09:02PM  
May-08-20 02:31PM  
May-07-20 01:57PM  
May-06-20 07:35PM  
Apr-29-20 12:33PM  
Apr-28-20 12:33PM  
Apr-23-20 06:00AM  
Apr-20-20 06:00AM  
Apr-14-20 04:41PM  
Apr-09-20 07:00AM  
Mar-25-20 11:30AM  
Mar-23-20 06:32PM  
Mar-20-20 08:02PM  
Mar-02-20 07:00AM  
Feb-27-20 02:49PM  
Feb-25-20 02:53PM  
Feb-24-20 06:15PM  
Feb-18-20 07:00AM  
Feb-17-20 12:30PM  
Feb-11-20 11:05PM  
Feb-05-20 10:27AM  
Jan-19-20 09:13AM  
Jan-07-20 04:48PM  
Dec-24-19 09:16AM  
Dec-23-19 08:15AM  
Dec-22-19 11:10AM  
Dec-10-19 12:22PM  
Dec-05-19 11:31AM  
Dec-03-19 07:50AM  
Nov-26-19 04:15PM  
Nov-09-19 10:43AM  
Nov-06-19 04:30PM  
Nov-05-19 06:35PM  
Oct-29-19 04:15PM  
Oct-28-19 05:49PM  
Oct-21-19 04:00PM  
Oct-07-19 10:25AM  
Oct-02-19 01:34PM  
Sep-25-19 04:05PM  
Sep-23-19 01:16PM  
Sep-10-19 01:58PM  
Sep-09-19 07:05AM  
Aug-28-19 04:30PM  
Aug-12-19 10:47AM  
Aug-11-19 08:32AM  
Aug-09-19 08:24AM  
Aug-07-19 11:20AM  
Aug-05-19 09:18AM  
Aug-02-19 05:44PM  
Aug-01-19 03:37PM  
Jul-31-19 03:27PM  
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease. Its product portfolio also include TD-1473, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY ELLIPTA for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Mylan Ireland Limited, Janssen Biotech, Inc., Alfasigma S.p.A, Trek Therapeutics, PBC, and Takeda Pharmaceutical Company Limited. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GRAHAM RICHARD ASVP, DevelopmentDec 14Sale19.477,500146,058123,749Dec 16 06:09 PM
WORBOYS PHILIP DSVP, Research & Transl ScienceDec 03Sale18.004,24676,428319,395Dec 07 06:42 PM
HAUMANN BRETT KChief Medical OfficerAug 21Sale18.2925,000457,240282,810Aug 24 06:21 PM
WORBOYS PHILIP DSVP, Research & Transl ScienceAug 20Sale18.0017,103307,854333,252Aug 24 06:38 PM